



Office de la Propriété
Intellectuelle
du Canada

Un organisme
d'Industrie Canada

Canadian
Intellectual Property
Office

An agency of
Industry Canada

CA 2106895 C 2004/01/06

(11)(21) **2 106 895**

(12) **BREVET CANADIEN
CANADIAN PATENT**

(13) **C**

(22) Date de dépôt/Filing Date: 1993/09/24

(41) Mise à la disp. pub./Open to Public Insp.: 1994/03/30

(45) Date de délivrance/Issue Date: 2004/01/06

(30) Priorité/Priority: 1992/09/29 (P42 32 561.7) DE

(51) Cl.Int.⁵/Int.Cl.⁵ A01N 43/50, A01N 43/78, A01N 47/44,
A01N 43/40

(72) Inventeurs/Inventors:
LOHR, REINHOLD, DE;
MUNDT, HANS-CHRISTIAN, DE;
ANDREWS, PETER, DE

(73) Propriétaire/Owner:
BAYER AKTIENGESELLSCHAFT, DE

(74) Agent: FETHERSTONHAUGH & CO.

(54) Titre : LUTTE CONTRE DES PARASITES DE POISSON

(54) Title: COMBATING FISH PARASITES

(57) Abrégé/Abstract:

The present invention relates to the use of agonists and antagonists of the nicotinerbic acetylcholine receptors of insects for combating fish parasites.



2106895

Combating fish parasites

Abstract

The present invention relates to the use of agonists and antagonists of the nicotinergetic acetylcholine receptors of insects for combating fish parasites.

Le A 29 050

The present invention relates to combating fish parasites using agents which contain agonists or antagonists of the nicotinerbic acetylcholine receptors of insects.

5 Intensive fish farming suffers substantial economic losses through damage to the fish which is caused by parasites such as fish-parasitising crustaceans such as, for example, the salmon louse or sea louse. Treatments against these parasites using metrifphonate or dichlorvos are known. These active substances must be employed in
10 relatively high concentrations and require a long period of treatment.

Other compounds for combating fish parasites are known from EP-OS (European Published Specification) 407 343.

15 It has now been found that agonists or antagonists of the nicotinerbic acetylcholine receptors of insects are outstandingly suitable for use against parasites in fish.

The agonists or antagonists of the nicotinerbic acetylcholine receptors of insects which can be used according to the invention are known from the following
20 publications:

European Published Specifications Nos. 464 830, 428 941, 425 978, 386 565, 383 091, 375 907, 364 844, 315 826, 259 738, 254 859, 235 725, 212 600, 192 060, 163 855,

154 178, 136 636, 303 570, 302 833, 306 696, 189 972,
455 000, 135 956, 471 372, 302 389;

German Published Specifications Nos. 3 639 877,
3 712 307;

5 Japanese Published Specifications Nos. 03 220 176,
02 207 083, 63 307 857, 63 287 764, 03 246 283, 04 9371,
03 279 359, 03 255 072;

U.S. Patents Nos. 5 034 524, 4 948 798, 4 918 086,
5 039 686, 5 034 404;

10 PCT Applications Nos. WO 91/17 659, 91/4965;


French Application No. 2 611 114;

Brazilian Application No. 88 03 621.

Reference is hereby explicitly made to the generic
formulae and definitions described in these publications,
15 as well as to the individual compounds described therein.

These compounds are partly summarised by the term nitro-
methylenes and compounds which are related thereto.

These compounds may preferably be summarised by the
general formula I



20

in which

23189-7545

R represents hydrogen, or acyl, alkyl, aryl, aralkyl, heteroaryl or heteroarylalkyl, each of which radicals may optionally be substituted;

A represents a monovalent group from the series
5 hydrogen, acyl, alkyl or aryl, or represents a divalent group, which is linked with the radical Z;

E represents an electron-withdrawing radical;

X represents the radicals -CH= or =N-, where the radical -CH= can be linked with the radical Z in place of an
10 H atom;

Z represents a monovalent group from the series alkyl,

-O-R, -S-R and $\begin{array}{c} \text{R} \\ \diagup \\ \text{N} \\ \diagdown \\ \text{R} \end{array}$ or represents a divalent
group

15 which is linked with the radical A or the radical X.

In one aspect, the invention provides use of agonists or antagonists of the nicotinerbic acetylcholine receptors of insects for combating fish parasites, wherein
20 the agonists or antagonists have the general formula I.

In a further aspect, the invention provides use of agonists or antagonists of the nicotinerbic acetylcholine receptors for preparing agents for combating fish parasites, wherein the agonists or antagonists have the general
25 formula I.

In a still further aspect, the invention provides

23189-7545

agents for combating fish parasites comprising agonists or antagonists of the nicotinergeric acetylcholine receptors, wherein the agonists or antagonists have the general formula I.

5 Particularly preferred compounds of the formula I are those in which the radicals have the following meaning:

R represents hydrogen as well as optionally substituted radicals from the series acyl, alkyl, aryl, aralkyl, heteroaryl and heteroarylalkyl.

10 Acyl radicals which may be metnioned are formyl, alkylcarbonyl, arylcarbonyl, alkylsulphonyl, aryl-

sulphonyl and (alkyl-)-(aryl-)-phosphoryl, which for their part may be substituted.

5 Alkyl which may be mentioned is C₁₋₁₀-alkyl, in particular C₁₋₄-alkyl, specifically methyl, ethyl, i-propyl or sec- or t-butyl, which for their part may be substituted.

Aryl which may be mentioned is phenyl or naphthyl, in particular phenyl.

10 Aralkyl which may be mentioned is phenylmethyl or phenethyl.

15 Heteroaryl which may be mentioned is heteroaryl having up to 10 ring atoms and N, O or S, in particular N, as heteroatoms. Thiophenyl, furyl, thiazolyl, imidazolyl, pyridyl or benzothiazolyl may specifically be mentioned.

Heteroarylalkyl which may be mentioned is heteroarylmethyl or heteroarylethyl having up to 6 ring atoms and N, O or S, in particular N, as heteroatoms.

20 Substituents which may be listed as examples and in preference are;
alkyl having preferably 1 to 4, in particular 1 or 2, carbon atoms, such as methyl, ethyl, n- and i-propyl and n-, i- and t-butyl; alkoxy having

preferably 1 to 4, in particular 1 or 2, carbon atoms, such as methoxy, ethoxy, n- and i-propyloxy and n-, i- and t-butyloxy; alkylthio having preferably 1 to 4, in particular 1 or 2, carbon atoms, such as methylthio, ethylthio, n- and i-propylthio and n-, i- and t-butylthio; halogenoalkyl having preferably 1 to 4, in particular 1 or 2, carbon atoms and preferably 1 to 5, in particular 1 to 3, halogen atoms, where the halogen atoms are identical or different and preferably fluorine, chlorine or bromine, in particular fluorine, are the halogen atoms, such as trifluoromethyl, or hydroxyl; halogen, preferably fluorine, chlorine, bromine and iodine, in particular fluorine, chlorine and bromine; cyano; nitro; amino; monoalkylamino and dialkylamino having preferably 1 to 4, in particular 1 or 2 carbon atoms per alkyl group, such as methylamino, methyl-ethyl-amino, n- and i-propyl-amino and methyl-n-butylamino; carboxyl; carbalkoxy having preferably 2 to 4, in particular 2 or 3, carbon atoms, such as carbomethoxy and carboethoxy; sulpho ($-\text{SO}_3\text{H}$); alkylsulphonyl having preferably 1 to 4, in particular 1 or 2, carbon atoms, such as methylsulphonyl and ethylsulphonyl; arylsulphonyl having preferably 6 or 10 aryl carbon atoms, such as phenylsulphonyl, as well as heteroarylamino and heteroarylalkylamino, such as chloropyridylamino and chloropyridylmethylamino.

A represents hydrogen and represents optionally substituted radicals from the series acyl, alkyl and aryl, which preferably have the meanings given above. Additionally, A represents a divalent group.
5 That which may be mentioned is optionally substituted alkylene having 1-4, in particular 1-2 C atoms, where the substituents which may be mentioned are those listed further above.

10 A and Z, together with the atoms to which they are bonded, may form a saturated or unsaturated heterocyclic ring. The heterocyclic ring can contain an additional 1 or 2 identical or different heteroatoms and/or hetero-groups. The heteroatoms are preferably oxygen, sulphur or nitrogen, and the
15 hetero-groups N-alkyl, where the alkyl of the N-alkyl group preferably contains 1 to 4, in particular 1 or 2, carbon atoms. alkyl which may be mentioned are methyl, ethyl, n- and i-propyl and n-, i- and t-butyl. The heterocyclic ring contains 5 to
20 7, preferably 5 or 6, ring members.

Examples of the heterocyclic ring which may be mentioned are pyrrolidine, piperidine, piperazine, hexamethyleneimine, morpholine and N-methylpiperazine.

25 E represents an electron-withdrawing radical, it being possible to mention in particular NO₂, CN or halogenoalkylcarbonyl, such as 1,5-halogeno-C₁₋₄-

carbonyl, in particular COCF_3 .

X represents $-\text{CH}=\text{}$ or $-\text{N}=\text{}$

Z represents optionally substituted radicals alkyl, $-\text{OR}$, $-\text{SR}$ or $-\text{NRR}$, with R and the substituents preferably having the abovementioned meaning.


Z can, together with the atom to which it is bound and the radical $\begin{array}{c} | \\ =\text{C}- \end{array}$ in place of X, form a saturated or unsaturated heterocyclic ring. The heterocyclic ring can contain an additional 1 or 2 identical or different heteroatoms and/or hetero-groups. The heteroatoms are preferably oxygen, sulphur or nitrogen, and the hetero-groups N-alkyl, with the alkyl or N-alkyl group preferably containing 1 to 4, in particular 1 or 2, carbon atoms. Alkyl radicals which may be mentioned are methyl, ethyl, n- and i-propyl and n-, i- and t-butyl. The heterocyclic ring contains 5 to 7, preferably 5 or 6, ring members.

Examples of the heterocyclic ring which may be mentioned are pyrrolidine, piperidine, piperazine, hexamethyleneimine, morpholine and N-methylpiperazine.

Compounds which are very particularly preferred for possible use according to the invention, and which may be mentioned, are compounds of the general formulae II and

23189-7545

III:




in which

n represents 1 or 2,

5 subst. represents one or more substituents listed above, particularly halogen, in particular chlorine,

A, Z, X and E have the abovementioned meanings,















in which



10 the radicals have the abovementioned meaning.

The following compounds may be specifically mentioned:

2106895







As already mentioned, the compounds which can be used according to the invention may be employed with outstanding effect for combating fish parasites, and in particular fish-parasitising crustaceans. Among these are the Copepoda (cyclops; fish-lice) with the genera

Ergasilus

Bromolochus

10 Chondracanthus

Caligus (- Caligus curtus)

Lepeophtheirus (- L. salmonis)

Elythrophora

Dichelestinum

15 Lamproglanz

	Hatschekia
	Legosphilus
	Symphodus
	Ceudrolasus
5	Pseudocycmus
	Lernaea
	Lernaeocera
	Pennella
	Achthares
10	Basanistes
	Salmincola
	Brachiella
	Epibrachiella
	Pseudotracheliastes
15	and the families
	Ergasilidae
	Bromolochidae
	Chondracanthidae
	Calijidae
20	Dichelestiidae
	Philichthyidae
	Pseudocycnidae
	Lernaeidae
	Lernaepodidae
25	Sphyriidae
	Cecropidae

as well as the Branchiuriae (carp lice) with the families

Argulidae and the genera *Argulus* spec.;

as well as the Cirripediae (cirripedes; barnacles) and *Ceratothoa gaudichaudii*.

5 The fish include food fish, cultivated fish, aquarium
fish and ornamental fish of all ages which live in fresh
water, sea water and pond water. The food fish and
cultivated fish include, for example, carp, eel, trout,
whitefish, salmon, bream, roach, rudd, chub, sole,
plaice, halibut, Japanese yellowtail (*Seriola*
10 *quinqueradiata*), Japanese eel (*Anguilla japonica*), red
sea bream (*Pagrus major*), sea bass (*Dicentrarchus*
labrax), grey mullet (*Mugilus cephalus*), pompano,
gilthead sea bream (*Sparus auratus*), *Tilapia* spp.,
cichlid species, such as, for example, plagioscion,
15 channel catfish. The agents according to the invention
are particularly suitable for treating fish fry, for
example carp of body length 2-4 cm. The agents are also
very suitable for eel fattening.

20 The treatment of the fish is effected either orally, for
example via the feed, or by balneotherapy, for example a
"medical bath" into which the fish are placed and in
which they are kept for a period (minutes to several
hours), for example in association with being moved from
one rearing pool to another. In particular cases, the
25 treatment can also be effected parenterally, for example
by injection.

Transient or permanent treatment may also take place of the habitat of the fish, for example in net cages, entire pond installations, aquaria, tanks or pools, in which the fish are kept.

5 The active substance is administered in preparations which are suited to the uses.

Preparations for oral use are powders, granules, solutions, emulsion concentrates or suspension concentrates which are mixed homogeneously with the feed as feed
10 additives.

Preparations for use as a bath or for treating the habitat are powders, granules, solutions, emulsion concentrates or suspension concentrates, emulsions or
15 suspensions, tablets or the active substance itself. The formulations can be employed by the user in diluted or undiluted form.

The preparations are prepared in a manner known per se, by mixing, granulating, grinding and/or compacting the active substance with solid or liquid carrier substances, optionally with the addition of further auxiliary substances such as emulsifying or dispersing agents, solubilisers, colorants, antioxidants or preservatives.
20

In contrast to the usual organophosphorus compounds, nitromethylenes are generally sufficiently soluble in water for the concentration to be used, and can therefore
25 also be employed undiluted.

However, more manageable preparations are those in which the active substance is present in diluted form. Suitable diluents for fish and other marine animals and plants are non-toxic substances, which can be liquid or solid, and, immediately prior to use according to the invention, water as well.

For practical use, films are also suitable which contain the active substance in a matrix which is readily soluble in water, or films containing the active, which will be released by diffusion.

The active substance itself, its micronised form or its solid formulations, can be used in water-soluble wrappings, for example in polyvinyl alcohol bags, together with the sealed pack. The user is then no longer exposed to the active substance or its formulations.

Semi-solid application forms can also be used for the balneotherapy. The active substance is washed out of greasy or fatty matrices in which it is suspended or dissolved. It is possible to control the release by the choice of auxiliary substances, and of the concentration and form (surface) of the active substance. Compressions or fusions of hard fats in which the active substance is present are also suitable, in occasion for oral use.

The diluted agents according to the invention are prepared by bringing the active substance of the formula I into contact with liquid and/or solid auxiliary formulation substances by step-wise mixing and/or grinding in

such a way that the anti-parasitic activity of the formulation is optimally displayed in conformity with the application.

5 The formulation steps may be supplemented by kneading, granulating, (granules) and optionally compressing, extruding or moulding (pellets and tablets).

10 Solid carrier substances, solvents and optionally surface-active substances (surfactants) which are not toxic for the marine flora and fauna serve, for example, as auxiliary formulation substances.

The following auxiliary formulation substances are used for preparing the agents according to the invention:

15 Solid carrier substances such as, for example, kaolin, talc, bentonite, sodium chloride, calcium phosphate, carbohydrates, cellulose powder, cotton seed meal or polyethylene glycol ether, optionally binding agents such as, for example, gelatin or soluble cellulose derivatives, if required with the addition of surface-active substances such as ionic or non-ionic dispersing agents;
20 in addition ground natural rocks such as calcite, montmorillonite or attapulgite. To improve the physical properties, highly disperse silicic acid or highly disperse absorbent polymers may also be added. Suitable granulated, adsorptive granule carriers are porous types,
25 such as, for example, pumice, crushed brick, sepiolite or bentonite, and suitable non-sorptive carrier materials

are, for example, calcite or sand. Beyond this, a multiplicity of pre-granulated materials of inorganic or organic nature, such as, in particular, dolomite or comminuted herbaceous material, can be used. Sorptive
5 organic materials, for example polyacrylates, can also be mixed with the active substance and brought into use.

Suitable solvents are: aromatic hydrocarbons, preferably the fractions C_8-C_{12} , for example, xylene mixtures or substituted naphthalenes, phthalates such as dibutyl
10 phthalate or dioctyl phthalate; aliphatic hydrocarbons such as, for example, cyclohexane or paraffins, alcohols and glycols as well as their ethers and esters, such as, for example, ethanol, ethylene glycol, ethylene glycol monomethyl ether or ethyl ether, ketones such as, for
15 example, cyclohexanone, strongly polar solvents, such as, for example, N-methyl-2-pyrrolidone, dimethyl sulphoxide or dimethylformamide, as well as optionally epoxidised vegetable oils, such as, for example, epoxidised coconut oil or soyabean oil and water.

20 In each case depending on the nature of the active substance of the formula I to be formulated, suitable surface-active compounds are non-ionic, cationic and/or anionic surfactants having good emulsifying, dispersing and wetting properties. Surfactants are also understood
25 to mean surfactant mixtures.

Suitable anionic surfactants may be so-called water-soluble soaps, as well as water-soluble synthetic

surface-active compounds.

2106895

5 Suitable soaps which may be are the alkali metal salts, alkaline earth metal salts or optionally substituted ammonium salts of higher fatty acids (C_{10} - C_{22}), such as, for example, the Na or K salts of oleic acid or stearic acid, or of natural fatty acid mixtures, which may be obtained, for example, from coconut oil or tallow oil.

10 Frequently, so-called synthetic surfactants are used, in particular fatty sulphonates, fatty sulphates, sulphonated benzimidazole derivatives or alkylsulphonates.

15 The fatty sulphonates or fatty sulphates are as a rule present as alkali metal salts, alkaline earth metal salts or optionally substituted ammonium salts and possess an alkyl radical having 8 to 22 C atoms, with alkyl also including the alkyl moiety of acyl radicals, for example the Na or Ca salt of lignosulphonic acid, of dodecyl sulphate or of a fatty alcohol sulphate mixture prepared from natural fatty acids. Among these are the salts of the sulphuric acid esters and sulphonic acids of fatty alcohol-ethylene oxide adducts. The sulphonated benzimidazole derivatives preferably contain 2 sulphonic acid groups and a fatty acid radical having 8-22 C atoms. Alkylarylsulphonates are, for example, the Na, Ca or triethanolamine salts of dodecylbenzenesulphonic acid, of 20 dibutylnaphthalenesulphonic acid or of a naphthalene-sulphonic acid-formaldehyde condensation product.

Additionally, corresponding phosphates, such as, for example, salts of the phosphoric acid ester of a p-nonylphenol-(4-14)-ethylene oxide adduct or phospholipids may be used as auxiliary formulation substances.

5 Suitable non-ionic surfactants are, in the first instance, polyglycol ether derivatives of aliphatic or cycloaliphatic alcohols, saturated or unsaturated fatty acids and alkylphenols, which may contain 3 to 30 glycol ether groups and 8 to 20 carbon atoms in the (aliphatic)
10 hydrocarbon radical and 6 to 18 carbon atoms in the alkyl radical of the alkylphenols.

Further suitable non-ionic surfactants are the water-soluble polyethyleneoxy adducts, containing 20 to 250 ethylene glycol ether groups and 10 to 100 propylene glycol ether groups, onto polypropylene glycol, ethylene-
15 diaminopolypropylene glycol and alkylpolypropylene glycol having 1 to 10 carbon atoms in the alkyl chain. The said compounds usually contain 1 to 5 ethylene glycol units per propylene glycol unit.

20 Examples of non-ionic surfactants which may be mentioned are nonylphenol-polyethoxyethanols, castor oil polyglycol ethers, polypropylene-polyethyleneoxy adducts, tributylphenoxypolyethoxyethanol, polyethylene glycol and octylphenoxypolyethoxyethanol.

25 In addition, fatty acid esters of polyoxyethylene sorbitan, such as polyoxyethylene sorbitan trioleate, are

also suitable.

5 The cationic surfactants are quaternary ammonium salts which contain as N-substituents at least one alkyl radical having 8 to 22 C atoms, and possess as further substituents lower, optionally halogenated, alkyl radicals, benzyl radicals or lower hydroxyalkyl radicals. The salts are preferably present as halides, methyl sulphates or ethyl sulphates, for example stearyltrimethylammonium chloride or benzyldi(2-chloroethyl)ethylammonium bromide.

10

The surfactants which are customarily employed in formulation technology are described, inter alia, in the following publications:

15 Mc Cutcheon's, Emulsifiers and Detergents, International Edition, New Jersey, USA, 1990;

20 Suitable binding agents for water-soluble granules or tablets are chemically modified polymeric natural substances which are soluble in water or alcohol, such as starch derivatives, cellulose derivatives or protein derivatives (e.g. methyl cellulose, carboxymethyl cellulose, ethylhydroxyethyl cellulose or proteins, such as zein, gelatin, and the like) as well as synthetic polymers, such as, for example, polyvinyl alcohol or polyvinylpyrrolidone etc. In addition, fillers, (e.g. starch,

25

microcrystalline cellulose, sugar or lactose etc.), lubricants and disintegrants are contained in tablets.

5 The balneary administration of the agents according to the invention onto the parasites which are to be controlled can be carried out by the agents being added to the cage in the form of solutions, emulsions, suspensions, powders or tablets, where they are rapidly dissolved and dispersed by the movement of the fish and by the water which is flowing through. Concentrated
10 solutions may also be diluted with relatively large volumes of water before being added to the cages. Concentration problems in the cages do not occur, inter alia because the fish, at each opening of the cages, become wildly agitated in the expectation of food and
15 thus ensure rapid dilution.

The anti-parasitic agents according to the invention contain, as a rule, 0.1 to 99% by weight, in particular 0.1 to 95% by weight, of active substance of the formula I, and 99.9 to 1% by weight, in particular 99.9 to 5% by
20 weight, of a solid or liquid additive, including 0 to 25% by weight, in particular 0.1 to 25% by weight, of a surfactant.

Whereas concentrated agents are more likely to be preferred as a commercial product, the consumer as a rule
25 uses diluted agents, which he obtains by diluting the commercial product with water.

Such agents may contain yet more additives, such as stabilisers, antifoam agents, viscosity regulators, binding agents, adhesives and other active substances for achieving special effects.

5 The concentration of the active substance during use depends on the nature and length of the treatment, as well as the age and condition of the fish which are being treated. In the case of a brief treatment, it is, for example, 0.1-100 mg of active substance per litre of
10 water, preferably 0.5-10 mg per litre, in the case of a treatment period of 0.3-4 hours.

In the treatment of ponds, 0.01-50 mg of active substance may be used per litre of water.

15 Preparations for use as a feed additive are composed as follows, for example:

	a)	Active substance of the formula I	1	- 10	parts by weight
		Soyabean protein	49	- 90	parts by weight
		Ground lime powder	0	- 50	parts by weight
20	b)	Active substance of the formula I	0.5	- 10	parts by weight
		Benzyl alcohol	0.08	- 1.4	parts by weight
		Hydroxypropyl methyl cellulose	0	- 3.5	parts by weight
		Water			Remainder to 100
25					

Preparations for use as a balneotherapeutic are dissolutions, emulsion- or suspension concentrates, for example:

2106895

5	c)	Active substance of the formula I	5.0%
		Anionic emulsifier	10.0%
		N-Methylpyrrolidone	25.0%
		Mineral oil	60.0%
10	d)	Active substance of the formula I	25.0%
		Anionic emulsifier	8.0%
		Non-ionic emulsifier	2.0%
		Dimethyl sulphoxide	35.0%
		N-Methylpyrrolidone	30.0%
15	e)	Active substance of the formula I	30.0%
		Urea	10.0%
		Polyvinyl alcohol	0.5%
		Gum (e.g. xanthan gum)	0.4%
		Preservative	0.1%
		Water	49.0%

Example A

20 In-vitro test against salmon louse


Glass dishes are filled with 40 ml of sea water and sufficient 0.1% (weight) or 10% (weight) solution of the active substance in ethanol is added to obtain the desired concentration for use. Sea water without active
25 substance, and sea water which has been mixed with the

2106895

corresponding quantity of ethanol without active substance, serve as controls.

5 adult salmon lice, which have been removed from naturally infected salmon, are placed in each glass dish. The glass dishes are kept at 10-12°C and checked after 1, 2, 5 and 24 hours. A record is taken of the number of test animals which are alive and the number which are dead. The results are summarised in the table:

Active substance:




Condition of the salmon lice after

	1	2	5	24 hours
Sea water	5 alive			5 alive
Sea water + 0.04 ml of ethanol	5 alive			5 alive
1 ppm of active sub- stance	4 alive 1 dead	5 dead		
100 ppm of active sub- stance	5 dead			0

23189-7545

CLAIMS:

1. Use of agonists or antagonists of the nicotinic acetylcholine receptors of insects for combating fish parasites, wherein the agonists or antagonists have the
5 general formula I:



wherein:

R represents hydrogen, or acyl, alkyl, aryl,
10 aralkyl, heteroaryl or heteroarylalkyl, each of which radicals may optionally be substituted;

A represents a monovalent group from the series hydrogen, acyl, alkyl or aryl, or represents a divalent group, which is linked with the radical Z;

15 E represents an electron-withdrawing radical;

X represents the radical $-\text{CH}=\text{}$ or $=\text{N}-$, where the radical $-\text{CH}=\text{}$ can be linked with the radical Z in place of an H atom;

Z represents a monovalent group from the series
20 alkyl,

$-\text{O}-\text{R}$, $-\text{S}-\text{R}$ and $\begin{array}{c} \text{R} \\ \diagup \\ -\text{N} \\ \diagdown \\ \text{R} \end{array}$ or represents a divalent
group

which is linked with the radical A or the radical X.


- 25 2. Use of agonists or antagonists of the nicotinic acetylcholine receptors according to claim 1 for combating

23189-7545

fish parasites from the genera Caligus, Lepeophtheirus and Argulus.

3. Use of agonists or antagonists of the nicotinerbic acetylcholine receptors according to claim 1 for combating
5 parasites in Salmo inidae, Oncorhynchus and Salvelinus.

4. Use of agonists or antagonists of the nicotinerbic acetylcholine receptors according to claim 1, 2 or 3, wherein general formula (I), R represents




wherein n is 1 or 2, and each ring may optionally be substituted by one or more substituents.












5. Use of agonists or antagonists of the nicotinerbic acetylcholine receptors according to claim 4, wherein the
15 substituent(s) is/are a halogen.

6. Use of agonists or antagonists of the nicotinerbic acetylcholine receptors according to claim 5, wherein the halogen is chlorine.


7. Use of agonists or antagonists of the nicotinerbic
20 acetylcholine receptors according to claim 1, 2 or 3, wherein general formula (I) represents a compound selected from the group consisting of:




23189-7545



, and



8. Use of agonists or antagonists of the nicotinic acetylcholine receptors according to claim 7, wherein the compound is:



23189-7545

9. Use of agonists or antagonists of the nicotinerpic acetylcholine receptors for preparing agents for combating fish parasites, wherein the agonists or antagonists have the general formula I as defined in any one of claims 1 and 4 to 5 8.

10. Agents for combating fish parasites comprising agonists or antagonists of the nicotinerpic acetylcholine receptors, wherein the agonists or antagonists have the general formula I as defined in any one of claims 1 and 4 10 to 8.

FETHERSTONHAUGH & CO.

OTTAWA, CANADA

PATENT AGENTS